The estimated Net Worth of Corp Incyte is at least $856 million dollars as of 16 June 2020. Corp Incyte owns over 214,000 units of Merus N.V stock worth over $853,400,831 and over the last 8 years Corp sold MRUS stock worth over $2,883,520.
Corp has made over 3 trades of the Merus N.V stock since 2017, according to the Form 4 filled with the SEC. Most recently Corp sold 214,000 units of MRUS stock worth $783,240 on 16 June 2020.
The largest trade Corp's ever made was buying 10,000,000 units of Merus N.V stock on 14 February 2017 worth over $60,000,000. On average, Corp trades about 2,697,750 units every 304 days since 2017. As of 16 June 2020 Corp still owns at least 16,972,968 units of Merus N.V stock.
You can see the complete history of Corp Incyte stock trades at the bottom of the page.
Corp's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON,, DE, 19803.
Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Merus N.V executives and other stock owners filed with the SEC include: